Direct inhibition of MYC has been challenging due to the short half-life of MYC oncoprotein and the high metabolism of the small molecule inhibitors, which has impeded the development of MYC inhibitors in clinical trials. However, Omomyc overcame these limitations, exuded potent anti-cancer effects, and has ascended toward clinical development for multiple cancers. Here, MYC is linked to cancer.